Ko 143
Chemical Name: (3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester
Purity: ≥99%
Biological Activity
Ko 143 is a potent and selective breast cancer resistance protein multidrug transporter (BCRP) inhibitor (EC90 = 26 nM). Displays > 200-fold selectivity over P-gp and MRP-1 transporters. Increases intracellular drug accumulation and reverses BCRP-mediated multidrug resistance. Inhibits ABCB1 and ABCC1 at higher concentrations. Rapidly metabolized in rat plasma.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
Barrier properties and transcriptome expression in human iPSC-derived models of the blood-brain barrier
L Delsing, P Dönnes, J Sánchez, M Clausen, D Voulgaris, A Falk, A Herland, G Brolén, H Zetterberg, R Hicks, J Synnergren
Stem Cells, 2018;0(0):. -
ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.
Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel Y, Fatima S, Kawauchi D, Shelat A, Stewart C, Sorrentino B, Schuetz J, Roussel M
Cancer Res, 2015;75(18):3879-89. -
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Zander, Serge A, Sol, Wendy, Greenberger, Lee, Zhang, Yixian, van Tellingen, Olaf, Jonkers, Jos, Borst, Piet, Rottenberg, Sven
PLoS ONE, 2012;7(9):e45248. -
PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter.
Hegedus C, Truta-Feles K, Antalffy G, Brozik A, Kasza I, Nemet K, Orban TI, Ozvegy-Laczka C, Varadi A, Sarkadi B
Biochem. Biophys. Res. Commun., 2012;420(4):869-74. -
E2F1 drives chemotherapeutic drug resistance via ABCG2.
Rosenfeldt M, Bell L, Long J, O'Prey J, Nixon C, Roberts F, Dufes C, Ryan K
Oncogene, 2014;33(32):4164-72. -
The inhibitor Ko143 is not specific for ABCG2.
Weidner et al.
J.Pharmacol.Exp.Ther., 2015;354:384 -
Potent and specific inhibition of breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Allen et al.
Mol.Cancer Ther., 2002;1:417 -
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etop. resistance and transport, but etop. oral availability is limited primarily by P-glycoprotein.
Allen et al.
Cancer Res., 2003;63:1339
Product Datasheets
Reconstitution Calculator
Molarity Calculator
Citations for Ko 143
The citations listed below are publications that use Tocris products. Selected citations for Ko 143 include:
13 Citations: Showing 1 - 10
-
IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process.
Authors: Coz Et al.
Oncotarget 2016;7:82511
-
Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier.
Authors: Kumar Et al.
Sci Rep 2016;6:20418
-
A role for ABCG2 beyond drug transport: Regulation of autophagy.
Authors: Ding Et al.
Autophagy 2016;12:737
-
ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.
Authors: Morfouace Et al.
Cancer Res 2015;75:3879
-
Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
Authors: Hoque Et al.
Biochem Pharmacol 2015;59:2572
-
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irino. in colon and lung cancer models with ABCG2-induced resistance.
Authors: Westover Et al.
Brain Res 2015;14:92
-
Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain.
Authors: Moreno-Sanz Et al.
Pharmacol Res 2014;87:87
-
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.
Authors: Hill Et al.
J Biol Chem 2013;85:29
-
Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
Authors: Moreno-Sanz Et al.
J Med Chem 2013;56:5917
-
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topo. resistance in BRCA1-deficient mouse mammary tumors.
Authors: Zander Et al.
PLoS One 2012;7:e45248
-
The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein.
Authors: Watson Et al.
Antimicrob Agents Chemother 2012;1436:111
-
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Authors: Lainey Et al.
Cell Cycle 2012;11:4079
-
The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system.
Authors: Moreno-Sanz Et al.
Pharmacol Res 2011;64:359
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for Ko 143
There are currently no reviews for this product. Be the first to review Ko 143 and earn rewards!
Have you used Ko 143?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image